1. Volume 71, Issue 6, Pages 896-903 (June 2017)
Why and Where do We Miss Significant Prostate Cancer with Multi-parametric Magnetic Resonance Imaging followed by Magnetic Resonance-guided and Transrectal Ultrasound-guided Biopsy in Biopsy-naïve Men? 
Martijn G. Schouten, Marloes van der Leest, Morgan Pokorny, Martijn Hoogenboom, Jelle O. Barentsz, Les C. Thompson, Jurgen J. Fütterer 
European Urology 
Volume 71, Issue 6, Pages (June 2017)
DOI: /j.eururo
Copyright © 2016 European Association of Urology Terms and Conditions

2. Fig. 1
Flowchart describing the diagnostic pathways. All patients underwent both multi-parametric magnetic resonance imaging (MRI) and transrectal ultrasound (TRUS)-guided biopsy. Patients with a Prostate Imaging Reporting and Data System (PI-RADS) ≥3 on multi-parametric MRI received MR image-guided biopsy in addition to TRUS biopsy.
European Urology  , DOI: ( /j.eururo )
Copyright © 2016 European Association of Urology Terms and Conditions

3. Fig. 2
Distribution maps of cancer positive segments in patients with significant prostate cancer on magnetic resonance image-guided biopsy (MR-Bx; left) and transrectal ultrasound-guided biopsy (TRUS-Bx; right). The anterior portion of the prostate was defined by a hypothetical line drawn 17mm anterior from the posterior prostatic surface irrespective of prostate size, which represents the core length commonly used during TRUS-Bx [17].
SV=seminal vesicles.
European Urology  , DOI: ( /j.eururo )
Copyright © 2016 European Association of Urology Terms and Conditions

4. Fig. 3
Distribution maps of the segments of significant prostate cancer lesions that were missed with magnetic resonance image-guided biopsy (MR-Bx; left) and transrectal ultrasound-guided biopsy (TRUS-Bx; right).
SV=seminal vesicles.
European Urology  , DOI: ( /j.eururo )
Copyright © 2016 European Association of Urology Terms and Conditions